Cadrenal Therapeutics, Inc.

Group 1 - The core valuation of CVKD is based on a probability adjusted DCF model, estimating a share value of $30.00 [1] - The model incorporates potential future revenues from tecarfarin in specific medical applications, including LVADs, ESKD+AFib, and mechanical heart valves [1] - The valuation is highly contingent on the continued clinical success of tecarfarin, with adjustments expected based on future clinical results [1]